Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1994 2
1995 1
1996 1
2000 1
2005 1
2007 2
2008 1
2009 1
2012 1
2013 1
2014 2
2015 2
2019 1
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y, Shi X, Ren J, Yi M, Han X. Bi Y, et al. Sci Rep. 2022 May 17;12(1):8136. doi: 10.1038/s41598-022-12334-x. Sci Rep. 2022. PMID: 35581365 Free PMC article.
The safety and efficacy of drug-eluting beads transarterial chemoembolization (DEB-TACE) for unresectable renal cell carcinoma (RCC) still unknown. We aimed to assess the feasibility, safety and clinical efficacy of DEB-TACE with doxorubicin-loa …
The safety and efficacy of drug-eluting beads transarterial chemoembolization (DEB-TACE) for unresectable renal cell …
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Grade 3-4 adverse events occurred in 47% of patients, including more frequently creatine phosphokinase (CPK) serum level elevation, neutropenia, hyponatremia, diarrhea, hand-food syndrome, oral mucositis and hypertension. CONCLUSIONS: The BREAKPOINT trial met its primary e …
Grade 3-4 adverse events occurred in 47% of patients, including more frequently creatine phosphokinase (CPK) serum level elevation, neutrope …
Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Suzuki K, et al. J Immunother. 2020 Jan;43(1):38-42. doi: 10.1097/CJI.0000000000000299. J Immunother. 2020. PMID: 31567704
A total of 49 consecutive patients with mRCC or unresectable renal cell carcinoma were treated with nivolumab at Kobe University Hospital between December 2016 and August 2018. ...We retrospectively collected the data of these 5 patients, including the …
A total of 49 consecutive patients with mRCC or unresectable renal cell carcinoma were treated with nivolumab at …
Targeted therapies in the treatment of advanced renal cell carcinoma.
Seront E, Machiels JP. Seront E, et al. Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):146-56. doi: 10.2174/157489209788452803. Recent Pat Anticancer Drug Discov. 2009. PMID: 19519537 Review.
This paper provides a comprehensive review of the new targeted therapies currently available in clinical practice to treat patients with metastatic unresectable renal cell carcinoma. ...
This paper provides a comprehensive review of the new targeted therapies currently available in clinical practice to treat patients w …
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME, Shah SN, Elson P, Garcia JA, Wood LS, Medsinge A, Campbell S, Dreicer R, Rini BI. Salem ME, et al. Clin Genitourin Cancer. 2014 Apr;12(2):117-23. doi: 10.1016/j.clgc.2013.08.001. Epub 2013 Oct 12. Clin Genitourin Cancer. 2014. PMID: 24126239
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset of patients. ...PATIENTS AND METHODS: CT scans of 27 patients with RCC (31 tumors) treated with neoadjuvant sunitinib were performed as part …
Neoadjuvant sunitinib might downsize unresectable renal cell carcinoma (RCC) and enable nephrectomy in a subset …
A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y, Hinata N, Omori T, Fujisawa M. Bando Y, et al. BMJ Open. 2019 Dec 10;9(12):e030522. doi: 10.1136/bmjopen-2019-030522. BMJ Open. 2019. PMID: 31826889 Free PMC article.
INTRODUCTION: Nivolumab has been proven to prolong overall survival as a second-line therapy for patients with advanced renal cell carcinoma (RCC) in a phase III clinical trial. However, versatile biomarkers have not been established to predict the efficacy of nivol …
INTRODUCTION: Nivolumab has been proven to prolong overall survival as a second-line therapy for patients with advanced renal cell carcinoma …
Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil.
Park JH, Kim SH, Han JK, Chung JW, Han MC. Park JH, et al. Cardiovasc Intervent Radiol. 1994 Nov-Dec;17(6):323-7. doi: 10.1007/BF00203951. Cardiovasc Intervent Radiol. 1994. PMID: 7533666
PURPOSE: The effectiveness of renal transcatheter arterial embolization (TAE) with a mixture of ethanol and iodized oil (Lipiodol) was analyzed retrospectively in 27 patients with unresectable renal cell carcinoma. METHODS: Symptomatic or permanent pal …
PURPOSE: The effectiveness of renal transcatheter arterial embolization (TAE) with a mixture of ethanol and iodized oil (Lipiodol) was analy …
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI. Eisen T, et al. Lancet Oncol. 2012 Oct;13(10):1055-62. doi: 10.1016/S1470-2045(12)70364-9. Epub 2012 Sep 6. Lancet Oncol. 2012. PMID: 22959186 Clinical Trial.
The primary efficacy endpoint was the proportion of patients who achieved an objective overall response, assessed in all patients who were evaluable for response. The trial has finished. This trial is registered with ClinicalTrials.gov, number NCT00664326. ...INTERP …
The primary efficacy endpoint was the proportion of patients who achieved an objective overall response, assessed in all patients who were e …
23 results